Cannformatics, in collaboration with Dr. Laszlo Mechtler, is planning to launch an observational clinical study focused on migraine patients who are successfully using cannabinoid-based products as part of their symptom management.

The study will apply Cannformatics's Cannabis-Responsive™ (C-Res™) biomarker technology to better understand how the
endocannabinoid system (ECS) functions in people with migraine,
and how cannabinoids may help restore balance.

Dr. Mechtler is an internationally recognized expert in neurology and
headache medicine as both a researcher and a clinician. Dr. Mechtler
is board-certified in neurology, neuroimaging, neuro-oncology, and
headache medicine, he serves as president of the DENT
Neurologic Institute and leads DENT’s cannabis clinic, which has
treated over 15,000 patients.

Cannformatics and Dr. Mechtler share a common goal to
personalize cannabinoid-based migraine care, moving it beyond
trial-and-error toward measurable, C-Res guided personalization.